Emergence of Carbapenem Non-susceptible &lt;i&gt;Campylobacter coli&lt;/i&gt; after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia

Hagiya, Hideharu; Kimura, Keigo; Nishi, Isao; Yoshida, Hisao; Yamamoto, Naoki; Akeda, Yukihiro; Tomono, Kazunori

doi:10.2169/internalmedicine.0312-17

Cited by 20 publications

(11 citation statements)

References 29 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbapenem-non-susceptible Campylobacter strains have already been reported (Hagiya et al, 2018). In Japan, C. coli isolates obtained successively from a patient after long-term treatment against recurrent bacteremia had an elevated MIC for meropenem (1 mg/L, then 4 mg/L).…”

Section: Overall Proposalmentioning

confidence: 97%

Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food‐producing animals and food

Aerts¹,

Battisti²,

Hendriksen³

et al. 2019

EFS2

View full text Add to dashboard Cite

Proposals to update the harmonised monitoring and reporting of antimicrobial resistance (AMR) from a public health perspective in Salmonella, Campylobacter coli, Campylobacter jejuni, Escherichia coli, Enterococcus faecalis, Enterococcus faecium and methicillin-resistant Staphylococcus aureus (MRSA) from food-producing animals and derived meat in the EU are presented in this report, accounting for recent trends in AMR, data collection needs and new scientific developments. Phenotypic monitoring of AMR in bacterial isolates, using microdilution methods for testing susceptibility and interpreting resistance using epidemiological cut-off values is reinforced, including further characterisation of those isolates of E. coli and Salmonella showing resistance to extended-spectrum cephalosporins and carbapenems, as well as the specific monitoring of ESBL/AmpC/carbapenemase-producing E. coli. Combinations of bacterial species, food-producing animals and meat, as well as antimicrobial panels have been reviewed and adapted, where deemed necessary. Considering differing sample sizes, numerical simulations have been performed to evaluate the related statistical power available for assessing occurrence and temporal trends in resistance, with a predetermined accuracy, to support the choice of harmonised sample size. Randomised sampling procedures, based on a generic proportionate stratified sampling process, have been reviewed and reinforced. Proposals to improve the harmonisation of monitoring of prevalence, genetic diversity and AMR in MRSA are presented. It is suggested to complement routine monitoring with specific cross-sectional surveys on MRSA in pigs and on AMR in bacteria from seafood and the environment. Whole genome sequencing (WGS) of isolates obtained from the specific monitoring of ESBL/AmpC/carbapenemase-producing E. coli is strongly advocated to be implemented, on a voluntary basis, over the validity period of the next legislation, with possible mandatory implementation by the end of the period; the gene sequences encoding for ESBL/AmpC/carbapenemases being reported to EFSA. Harmonised protocols for WGS analysis/ interpretation and external quality assurance programmes are planned to be provided by the EU-Reference Laboratory on AMR.

show abstract

Section: Overall Proposalmentioning

confidence: 97%

Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food‐producing animals and food

Aerts¹,

Battisti²,

Hendriksen³

et al. 2019

EFS2

View full text Add to dashboard Cite

show abstract

“…Over the past 30 years, carbapenems have played a crucial role in clinical weaponry to treat serious infections in patients primarily affected by multidrug-resistant bacteria. However, the usefulness of this class of antibiotics is being c o m p r o m i s e d b y t h e e m e r g e n c e o f r e s i s t a n c e i n Enterobacteriaceae and especially in Campylobacteriaceae, being considered as a "nightmare" (Perez et al, 2016;Hagiya et al, 2018). In our study, two of these three strains have erythromycin as a treatment option, but one of them, in addition to resistance to meropenem, was also resistant to all other classes of tested antimicrobials.…”

Section: Antimicrobial Resistance Profile In the Planktonic Formmentioning

confidence: 99%

“…For severe infections caused by carbapenemase-producing Enterobacteriaceae, the possibility of treatment is the use of colistin, either singly or in combination with other antibiotics, which does not fit Campylobacter due to its intrinsic resistance (Halaby et al, 2013). Although resistance to carbapenemics in Campylobacter has not yet been well defined by the authorities, a study by Hagiya et al (2018) suggested the existence of resistance due to subsequent exposure to the drug in a clinical situation. Our study demonstrates the first record of phenotypic resistance to meropenem in C. jejuni in Brazil.…”

Section: Antimicrobial Resistance Profile In the Planktonic Formmentioning

confidence: 99%

Antibiotic Resistance in the Alternative Lifestyles of Campylobacter jejuni

Rossi

Dumont

Santos

et al. 2021

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Campylobacter jejuni is the main pathogen identified in cases of foodborne gastroenteritis worldwide. Its importance in poultry production and public health is highlighted due to the growing antimicrobial resistance. Our study comparatively investigated the effect of five different classes of antimicrobials on the planktonic and biofilm forms of 35 strains of C. jejuni with high phylogenetic distinction in 30 of them. In the planktonic form, the existence of susceptible strains to colistin (7/35 – 20%) and resistance to meropenem (3/35 – 8.6%) represent a novelty in strains evaluated in Brazil. In biofilms formed with the addition of chicken juice, the number of resistant strains was significantly higher for colistin, erythromycin and meropenem (100%), but the susceptibility to tetracycline was shown as a control strategy for specific cases. High concentrations (1,060 ± 172.1mg/L) of antibiotics were necessary to control the biofilm structure in susceptible strains in the planktonic form, which is consistent with the high biomass produced in these strains. Stainless steel and polyurethane were the most (BFI=2.1) and least (BFI=1.6) favorable surfaces for the production of biomass treated with antimicrobials. It is concluded that the antimicrobial action was detected for all tested drugs in planktonic form. In sessile forms, the biomass production was intensified, except for tetracycline, which showed an antibiofilm effect.

show abstract

“…Lastly, there is a case report of Campylobacter coli repeatedly treated with TBP‐PI and faropenem in an adult patient who subsequently developed resistance to TBP‐PI 62 . However, this is also likely due to the underdosing of TBP‐PI in an adult patient as there was no adult dosing guidance available to the clinicians who utilized 200 mg by mouth twice daily (BID).…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

Tebipenem pivoxil hydrobromide—No PICC, no problem!

et al. 2021

View full text Add to dashboard Cite

Tebipenem pivoxil hydrobromide is a novel orally bioavailable prodrug of tebipenem, a carbapenem antimicrobial, that binds to penicillin‐binding proteins, inhibiting the synthesis of the bacterial cell wall. This results in weakening of peptidoglycan, leading to lysis of bacterial cells. Tebipenem displays a broad spectrum of activity against anaerobic, gram‐positive, and gram‐negative pathogens, including extended‐spectrum β‐lactamase producing Enterobacterales. In a large phase 3 clinical trial (ADAPT‐PO), oral tebipenem pivoxil hydrobromide 600 mg every 8 h was shown to be non‐inferior to intravenous ertapenem 1 g every 24 h. Overall response at test of cure was 58.8% [264/449] in the tebipenem pivoxil hydrobromide group compared to 61.6% [258/419] in the ertapenem group for the treatment of complicated urinary tract infections, including acute pyelonephritis. At the test of cure, clinical cure rates were 93.1% and 93.6% and microbiological eradication was 59.5% and 63.5% with tebipenem pivoxil hydrobromide and ertapenem, respectively. The most common adverse reactions associated with tebipenem pivoxil hydrobromide are diarrhea, headache, and nausea. As with other carbapenems, tebipenem pivoxil hydrobromide is expected to have the potential to decrease the seizure threshold and will likely require renal dosage adjustment for patients with altered renal function due to high renal clearance. If approved in the United States, tebipenem pivoxil hydrobromide can serve as a potential oral antimicrobial option to decrease hospital length of stay and prevent hospital admissions due to resistant pathogens.

show abstract

Emergence of Carbapenem Non-susceptible <i>Campylobacter coli</i> after Long-term Treatment against Recurrent Bacteremia in a Patient with X-linked Agammaglobulinemia

Cited by 20 publications

References 29 publications

Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food‐producing animals and food

Technical specifications on harmonised monitoring of antimicrobial resistance in zoonotic and indicator bacteria from food‐producing animals and food

Antibiotic Resistance in the Alternative Lifestyles of Campylobacter jejuni

Tebipenem pivoxil hydrobromide—No PICC, no problem!

Contact Info

Product

Resources

About